4DMT to Participate in Upcoming Investor Meetings
Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) said management will present and hold one-on-one investor meetings at upcoming conferences in March 2026.
Scheduled events include the Leerink Partners Mountain Meeting (March 22–25, 2026) and a presentation at the RBC Capital Markets Global Ophthalmology Conference on March 24, 2026 at 3:45 p.m. GMT. An archived webcast will be available for up to one year on the company Investors site.
Positive
- None.
Negative
- None.
News Market Reaction – FDMT
In the Mar 16 session, FDMT gained 1.80%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in March.
| Leerink Partners Mountain Meeting | |
| Event Date: | March 22-25, 2026 |
| RBC Capital Markets Global Ophthalmology Conference | |
| Presentation Date: | Tuesday, March 24, 2026 |
| Presentation Time: | 3:45 p.m. GMT |
An archived copy of the webcast will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Jenn Gordon
dna Communications
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com
